Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › ANTHEM

ANTHEM

Anthem Biosciences Limited
Mid-capPharma ↗

What the six lenses say about ANTHEM — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹933.5
2026-09-08
VWAP · 1Y anchor
₹760
+22.8% from VWAP
P/E · TTM
88.6×
TTM EPS ₹10.5
52-week range
95%
position low→high
RSI(14)
65
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How ANTHEM’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
6.5
avg conviction decile
Leadership
Leader
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Mid-cap cohortDRaw
TechnicalD10100›

The actual numbers

Price vs VWAP (1y)+22.8%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+20.8%
Price vs 50-EMA+9.8%
RSI(14)65
RS vs Nifty 500 · 3M+16.3%
RS vs sector · 3M+10.3%
52-week range95%
Volume vs 30d avg1.16×
Volume vs 60d avg1.15×
ATR(14) · volatility35.0
Bollinger width · vol contraction0.109
FundamentalD1087›

The actual numbers

Return on equity (ROE)22.3%
Return on capital (ROCE)30.4%
Operating margin39.1%
Net margin27.9%
Revenue growth · YoY+15.1%
EPS growth · YoY+30.6%
Debt / equity0.02×

Full 8-quarter history in the financials table below.

ValuationD10›

The actual numbers

P/E (TTM)88.6×
TTM EPS₹10.5
52-week range95%
CatalystD648›

The actual numbers

Earnings & momentum49
Capital actions44
Governance50

Every filing in the corporate-announcements panel below.

FlowD350›

The actual numbers

Promoter holding74.7%
Delivery · 30d avg55.1%
Up/down-day asymmetry-1.2pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Mid-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D10 + D3 ) ÷ 2 = 6.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
95
Conviction score 95/100 · avg-decile strength 6.5/10
Conviction score95/100›
TechnicalD10›
FundamentalD10›
ValuationD1›
CatalystD6›
FlowD3›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+0.4pp
+5.8pp
+16.5pp
+17.9pp
+43.5pp
+18.4pp
Nifty 500
Broad-market baseline
+0.4pp
+5.8pp
+15.5pp
+16.3pp
+37.8pp
+13.2pp
Sector
Own-sector index
—
—
+12.6pp
+10.3pp
+24.6pp
-7.6pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

ANTHEM daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
933.50-0.55

Relative strength

RS vs baseline · rebased to 100

ANTHEM ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
129.04+0.47

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)339525498483540550423611
↳ change QoQ—+54.9%-5.1%-3.0%+11.8%+1.9%-23.1%+44.4%
EBITDA (₹cr)121195160195191218157267
EBITDA margin35.7%37.1%32.1%40.4%35.4%39.6%37.1%43.7%
PAT (₹cr)821621248313617393190
↳ change QoQ—+97.6%-23.5%-33.1%+63.9%+27.2%-46.2%+104.3%
Net margin24.2%30.9%24.9%17.2%25.2%31.4%22.0%31.1%
EPS (₹)1.472.902.221.482.423.091.653.38
D/E————————
YoY growth · Mar '26Revenue +26.5% YoYPAT +128.9% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 8 Sep '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 21 Jul '26
    MEDIUMcapital
    Press Release (Revised)
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 21 Jul '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 21 Jul '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 21 Jul '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 21 Jul '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 15 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 8 Jul '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 8 Jul '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 3 Jul '26
    MEDIUMcapital
    Credit Rating
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 2 Jul '26
    HIGHearnings
    Reply to Clarification- Financial results
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 30 Jun '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Jun '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds ANTHEM

Mutual funds holding ANTHEM (10)

FundWeightAUM ₹crGrade
HDFC Flexi Cap Gr0.61%1,10,736
Axis ELSS Tax Saver Fd Gr0.73%32,592
Aditya BSL Flexi Cap Gr0.71%28,112
SBI Midcap Reg Gr1.43%24,354
Axis Large & Mid Cap Reg Gr0.51%16,802
Kotak Multi Asset Allocation Reg Gr0.87%14,770
Axis Flexi Cap Reg Gr0.72%13,478
UTI Mid Cap Reg Gr1.43%12,379
PGIM India Midcap Fund Reg Gr0.67%11,071
Kotak Large Cap Reg Gr0.55%11,028

ETFs holding ANTHEM (3)

ETFWeightGrade
Motilal Oswal BSE Select IPO ETF0.91%
Motilal Oswal BSE Healthcare ETF0.70%
Mirae Asset Nifty 500 Healthcare ETF0.52%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma